BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $281,917 | -21.9% | 7,470 | -5.8% | 0.01% | -20.0% |
| Q2 2023 | $361,108 | +11.3% | 7,926 | -0.9% | 0.02% | +7.1% |
| Q1 2023 | $324,561 | -29.8% | 8,002 | -11.7% | 0.01% | -33.3% |
| Q4 2022 | $462,094 | -5.3% | 9,066 | 0.0% | 0.02% | -8.7% |
| Q3 2022 | $488,000 | -26.5% | 9,066 | -12.4% | 0.02% | -20.7% |
| Q2 2022 | $664,000 | -5.9% | 10,344 | +13.6% | 0.03% | +3.6% |
| Q1 2022 | $706,000 | -9.3% | 9,105 | +0.5% | 0.03% | -3.4% |
| Q4 2021 | $778,000 | +11.6% | 9,062 | +4.6% | 0.03% | 0.0% |
| Q3 2021 | $697,000 | -0.7% | 8,667 | -0.6% | 0.03% | 0.0% |
| Q2 2021 | $702,000 | -2.1% | 8,717 | +2.5% | 0.03% | -3.3% |
| Q1 2021 | $717,000 | +0.8% | 8,504 | -4.1% | 0.03% | -6.2% |
| Q4 2020 | $711,000 | -1.1% | 8,864 | -0.8% | 0.03% | -8.6% |
| Q3 2020 | $719,000 | -15.6% | 8,937 | -9.7% | 0.04% | -25.5% |
| Q2 2020 | $852,000 | 0.0% | 9,897 | -5.6% | 0.05% | -11.3% |
| Q1 2020 | $852,000 | -5.5% | 10,488 | -2.8% | 0.05% | +17.8% |
| Q4 2019 | $902,000 | -3.6% | 10,789 | +0.8% | 0.04% | -10.0% |
| Q3 2019 | $936,000 | +8.5% | 10,703 | +1.6% | 0.05% | +4.2% |
| Q2 2019 | $863,000 | -7.6% | 10,538 | -8.3% | 0.05% | -11.1% |
| Q1 2019 | $934,000 | +32.9% | 11,486 | +7.5% | 0.05% | +12.5% |
| Q4 2018 | $703,000 | -14.6% | 10,681 | 0.0% | 0.05% | -4.0% |
| Q3 2018 | $823,000 | -15.8% | 10,681 | -19.3% | 0.05% | -15.3% |
| Q2 2018 | $978,000 | +20.4% | 13,239 | +6.0% | 0.06% | +13.5% |
| Q1 2018 | $812,000 | +23.4% | 12,486 | +22.7% | 0.05% | +23.8% |
| Q4 2017 | $658,000 | +1.4% | 10,172 | -1.6% | 0.04% | -2.3% |
| Q3 2017 | $649,000 | +3.7% | 10,338 | 0.0% | 0.04% | -4.4% |
| Q2 2017 | $626,000 | +34.6% | 10,338 | +15.3% | 0.04% | +32.4% |
| Q1 2017 | $465,000 | +10.5% | 8,967 | -5.7% | 0.03% | 0.0% |
| Q4 2016 | $421,000 | -5.8% | 9,507 | +1.3% | 0.03% | -29.2% |
| Q3 2016 | $447,000 | +6.7% | 9,389 | +1.2% | 0.05% | +2.1% |
| Q2 2016 | $419,000 | +8.8% | 9,274 | -1.0% | 0.05% | +4.4% |
| Q1 2016 | $385,000 | -9.4% | 9,368 | -16.0% | 0.04% | -11.8% |
| Q4 2015 | $425,000 | +15.5% | 11,149 | -0.5% | 0.05% | +2.0% |
| Q3 2015 | $368,000 | -87.5% | 11,207 | -73.4% | 0.05% | -87.0% |
| Q2 2015 | $2,946,000 | -3.6% | 42,126 | -5.6% | 0.38% | -7.5% |
| Q1 2015 | $3,056,000 | -2.2% | 44,610 | +4.6% | 0.42% | -9.6% |
| Q4 2014 | $3,126,000 | +7.6% | 42,642 | +5.3% | 0.46% | -1.1% |
| Q3 2014 | $2,905,000 | +2.1% | 40,481 | +2.8% | 0.46% | -3.1% |
| Q2 2014 | $2,846,000 | +62.4% | 39,371 | +65.2% | 0.48% | +46.3% |
| Q1 2014 | $1,753,000 | +11.0% | 23,834 | +5.0% | 0.33% | +0.6% |
| Q4 2013 | $1,579,000 | +17.0% | 22,705 | +10.4% | 0.33% | -2.7% |
| Q3 2013 | $1,350,000 | +50.3% | 20,560 | +59.8% | 0.34% | +24.1% |
| Q2 2013 | $898,000 | – | 12,864 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |